U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06818955) titled 'Orlistat Overcoming Third-generation EGFR-TKI Resistance' on Feb. 03.
Brief Summary: EGFR mutation positivity accounts for 50% of lung adenocarcinoma cases. Multiple clinical trials, represented by FLAURA, AENEAS, and FURLONG studies, have confirmed that third-generation EGFR-TKI can provide significant benefits to patients with EGFR sensitive mutations and has become the first-line preferred treatment for EGFR mutation positive NSCLC, with a median PFS of around 19 and OS of around 38 months. These large-scale Phase III studies have confirmed the excellent efficacy of third-generation EGFR-TKI in EGFR mutation positive patients. Ho...